KRYS News and Press, Krystal Biotech Inc. From 09/04/19

Krystal Biotech ( KRYS +2% ) launches a Phase 1/2 clinical trial, GEM-3 , evaluating gene therapy KR105 in patients with transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (ARCI), a rare inherited disorder characterized by thick scaling of the skin affecting ~...

PITTSBURGH, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient aut...

PITTSBURGH, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman a...

Krystal Biotech (NASDAQ: KRYS ): Q2 GAAP EPS of -$0.37 misses by $0.05 . More news on: Krystal Biotech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

FDA grants RMAT designation for KB103 to treat dystrophic epidermolysis bullosa (DEB) Announced positive results from Phase 2 trial (“GEM-2”) of KB103 Submitted an IND application to initiate a Phase 1/2, first in-human trial of KB105 to treat patients with TGM1-defic...

There are many bad actors involved in Abeona who have a long history of shareholder value destruction We initially exposed Abeona for the low-quality biotech it is back in December 2016. We recommend readers refamiliarize themselves with our two reports on the company ( here and here ). ...

Introduction Every year the Russell Indexes are rebalanced to bring in new stocks and remove underperforming stocks. The FTSE Russell calls this event the annual reconstitution process, and it begins with evaluations in May and moves to the selection process on June 7th with the newly recons...

Introduction Every year the Russell Indexes are rebalanced to bring in new stocks and remove underperforming stocks. The FTSE Russell calls this event the annual reconstitution process, and it begins with evaluations in May and moves to the selection process on June 7th with the newly recons...

PITTSBURGH, July 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat skin diseases, today announces that it has been added to the Russell 2000 ®  Index, effective after the stock mark...

PITTSBURGH, July 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat skin diseases, today announces that it has been added to the Russell 2000 ®  Index, effective after the stock mark...